Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adrecizumab in moderate to severe COVID-19
NCT05156671Phase 2Terminated
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Oct 2022
- Primary completion
- Aug 2023
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Adrecizumab with Placebo (2 arms). Primary endpoint: Time to clinical improvement at 90 days. Started Oct 2022; status: terminated.
02
Drugs
adrecizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05156671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156671.